Cardiovascular risks in patients with type 2 diabetes mellitus and obesity
Abstract Objective: To assess the impact of variability of blood glucose in patients with type 2 diabetes mellitus and hypertension on indicators of cardiovascular risk in patients receiving the drug reduxine and weight loss.
Materials and Methods: The study included 80 patients. 50 in the intervention group and 30 people in the control group. The groups were similar in mean age, weight, duration of diabetes, BMI. At baseline, all patients had a diagnosis of type 2 diabetes mellitus and arterial hypertension. The parameters were evaluated before and after 6 months of therapy reduxine.
Results: Initially among the patients of the main groups and observation was no significant difference in the results of ECG, Holter monitoring, as well as in the results of analyzes lipid and glycemic control. We evaluated the dynamics of indicators in the study group patients and safety compared to the control group. Body weight in the intervention group decreased by observing 8,4% (p<0,001). Fasting glucose level decreased by 16% (p<0,001), HbA1c by 10,5% (p<0,001). Glycemic variability decreased on average by 50% (p<0,001). The level of leptin in the main observation group decreased by 71,8% (p<0,001). The level of OX in the main observation group decreased by 7% (p<0,05). TG levels in blood decreased by 28,2% (p<0,05). There were no hypoglycaemiс events noted during the research. According to Holter monitoring in the main group monitoring the therapy showed improvement of blood pressure, including in comparison with observation. Mean SBP decreased during treatment by 11,1%, DBP by 13% (p<0,001). According important ECG changes, including the control group were not recorded. In addition, we had tolerability of the combined therapy with reduxin and OADs. More than 90% of patients were satisfied with the treatment.
Conclusions: The analysis obtained in the course of our research data has shown that weight loss in patients with diabetes, hypertension and overweight in patients receiving the drug reduxine has a positive effect on the performance is regarded by the medical community as affecting the cardiovascular risks. There was observed a statistically significant decrease of glycemia – voltage variation, the level of leptin, TC and TG, improving cardiovascular control. Provided data suggest a beneficial effect of the active weight loss on the lipid and glycemic profile, lipo- and glucosetoxicity that promise to reduce cardiovascular risks.
Keywords:cardiovascular risks, type 2 diabetes mellitus, obesity, glycemic variability